Figure 2. IOP (mmHg) measurements in rat eyes receiving biweekly IC injections of TGF-β1+siRhoA, TGF-β1+siEGFP, and PBS. Note the statistically significant acute intraocular pressure (IOP) rise between 3 days and 7 days in the TGF-β1+siEGFP-injected group compared to the TGF-β1+siRhoA- and PBS-injected groups (*p<0.05) and the lack of a statistically significant difference between the TGF-β1+siRhoA- and the TGF-β1+siEGFP-injected eyes in the chronic phase (13 days to 35 days). The TGF-β1+siRhoA- and TGF-β1+siEGFP-injected eyes were statistically significantly different from control PBS-injected eyes in the chronic phase (13 days to 35 days;** p<0.05). TGF-β1+siEGFP intraocular pressure (IOP) values were not statistically significantly different from those in rats receiving TGF-β1 alone (IOP for TGF-β1 alone was previously reported [34]).